

(19)



(11)

EP 4 149 460 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(48) Corrigendum issued on:
08.01.2025 Bulletin 2025/02

(45) Date of publication and mention
of the grant of the patent:
27.11.2024 Bulletin 2024/48

(21) Application number: **21725377.2**

(22) Date of filing: **13.05.2021**

(51) International Patent Classification (IPC):
A61K 31/4045 ^(2006.01) **A61P 25/18** ^(2006.01)
A61P 25/22 ^(2006.01) **A61P 25/24** ^(2006.01)
A61P 25/30 ^(2006.01) **C07D 209/16** ^(2006.01)
A61K 9/16 ^(2006.01) **A61K 9/20** ^(2006.01)
A61K 9/48 ^(2006.01) **A61K 45/06** ^(2006.01)
A61P 25/00 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
C07D 209/16; A61K 31/4045; A61K 45/06;
A61P 25/00; A61P 25/18; A61P 25/22; A61P 25/24;
A61P 25/30; A61K 9/2009; A61K 9/2013;
A61K 9/2027; A61K 9/2059; A61K 9/485;
A61K 9/4858; A61K 9/4866 (Cont.)

(86) International application number:
PCT/EP2021/062794

(87) International publication number:
WO 2021/244831 (09.12.2021 Gazette 2021/49)

(54) **THERAPEUTIC SOLID DOSAGE FORMS**

FESTE THERAPEUTISCHE DARREICHUNGSFORMEN

FORMES GALÉNIQUES SOLIDES THÉRAPEUTIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO RS SE SI SK SM TR

(30) Priority: **02.06.2020 PCT/EP2020/065244**
02.06.2020 GB 202008303
02.06.2020 US 202016890664
01.12.2020 GB 202018950
01.12.2020 GB 202018955
01.12.2020 US 202017108679
01.12.2020 US 202017108938
22.03.2021 GB 202103981
22.03.2021 US 202117208583
23.04.2021 PCT/EP2021/060750

(43) Date of publication of application:
22.03.2023 Bulletin 2023/12

(60) Divisional application:
24215587.7

(73) Proprietor: **Cybin UK Ltd**
London EC1Y 8RT (GB)

(72) Inventors:
• **RANDS, Peter**
London EC2A 4BX (GB)
• **BENWAY, Tiffanie**
London EC2A 4BX (GB)
• **JOEL, Zelah**
London EC2A 4BX (GB)
• **LAYZELL, Marie**
London EC2A 4BX (GB)
• **JAMES, Ellen**
London EC2A 4BX (GB)

(74) Representative: **Patent Boutique LLP**
10A Printing House Yard
Hackney Road
London E2 7PR (GB)

(56) References cited:
WO-A1-2019/081764 WO-A1-2020/245133

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 4 149 460 B8

- **SIMON D. BRANDT ET AL:** "Microwave-accelerated synthesis of psychoactive deuterated N , N -dialkylated-[α] , [α] , [β] , [β] -d 4]-tryptamines", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 51, no. 14, 1 November 2008 (2008-11-01), GB, pages 423 - 429, XP055724013, ISSN: 0362-4803, DOI: 10.1002/jlcr.1557
- **MORRIS ET AL.:** "Indolealkylamine metabolism: Synthesis of deuterated indolealkylamines as metabolic probes", JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 33, no. 6, 1993, pages 455 - 465, XP009522345, DOI: 10.1002/jlcr.2580330603
- **BEATON J M ET AL:** "A comparison of the behavioral effects of proteo- and deuterio-N, N-dimethyltryptamine", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 16, no. 5, 1 May 1982 (1982-05-01), pages 811 - 814, XP023806754, ISSN: 0091-3057, DOI: 10.1016/0091-3057(82)90240-4

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/4045, A61K 2300/00